Schering takes Primovist MRI (magnetic resonance imaging) liver agent to Sweden:
This article was originally published in Clinica
Schering has moved a step closer to selling its MRI-based liver contrast agent throughout Europe, after gaining market approval for the product in Sweden. Primovist is a gadolinium-based contrast medium that is specifically taken up by liver cells. It is designed to simultaneously detect, locate and distinguish various types of liver lesions, including liver tumours, metastases and other malignant and benign lesions. Based on the Swedish registration, the Berlin, Germany company said it would start a mutual recognition procedure for the EU, with Sweden acting as reference member state. EU registration is expected in most countries within 2004, the firm predicted. Submissions for approval in Japan and other Asian countries, where liver examinations are particularly frequent, are also planned to take place this year.